Episode 26 - David-Alexandre "DA" Gros, CEO & Director of Eledon Pharmaceuticals

Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David-Alexandre "DA" Gros, a seasoned leader in the biotech industry and the current CEO & Director of Eledon Pharmaceuticals. DA's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO Imbria Pharmaceuticals, President and Chief Operating Officer of Neurocrine Biosciences, Chief Business and Principal Financial Officer at Alynlam Pharmaceuticals, Chief Strategy Officer and EVP, Strategy & Business Development at Sanofi, Principal, Healthcare Investment Banking at Centerview Partners & Vice President, Healthcare Investment Banking at Merrill Lynch. Now, at the helm of Eledon Pharmaceuticals, Eledon are focused on striving to both extend the functional life of transplanted organs and reduce side effects of current immunosuppressive treatments such as kidney toxicity, high blood pressure, and tremor. DA's deep expertise, from startups to larger pharmaceutical companies gives him a unique perspective on how to steer innovative science towards tangible clinical outcomes. We're excited to dive into his journey, the challenges and successes along the way, changing career lanes & the business development landscape.